Company
LON:APH
Alliance Pharma PLC is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries. The company holds marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential.
156 stories · page 4 of 8
"We are cautious about the outlook for the year ahead, but we remain confident that we have the resources and personnel to deliver profitability to our shareholders," Tandem said.
The AIM-listed speciality pharmaceutical group said Peter Butterfield, currently deputy CEO, will take over from John Dawson as CEO on 1 May 2018
Investments and investor services
Investors didn't want to venture into shares today, or outside much in the UK for that matter
Tyratech shares were up around 10% on Thursday while Alliance also edged into positive territory
Investments and investor services
The FTSE 100 finished little changed at 7,622 on the back of a rally in mining shares.
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
By the time it has confirmed press speculation, the bid approach was a dead duck
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech plc, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
FTSE 100 closed over 38 points higher on the day to 7,338; FTSE 250 shares added over 81
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Some of the biggest risers and fallers in London on Friday.
John Dawson, Alliance Pharma's chief executive, said: "The acquisition will be immediately earnings enhancing, accretive to our underlying return on invested capital, and it fits well in our existing bedrock business operations"
Investments and investor services
The Teflon president faced another test of his lucky rabbit's foot's effectiveness
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
